Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RIPK2 | O43353 | 10/20 | 0.44 |
| ▸ | TNK2 | Q07912 | 4/20 | 0.43 |
| ▸ | ACVR1 | Q04771 | 5/20 | 0.42 |
| ▸ | NOD2 | Q9HC29 | 6/20 | 0.41 |
| ▸ | PTK2 | Q05397 | 2/20 | 0.40 |
| ▸ | WEE1 | P30291 | 1/20 | 0.40 |
| ▸ | AURKA | O14965 | 1/20 | 0.40 |
| ▸ | CDK4 | P11802 | 1/20 | 0.40 |
| ▸ | JAK2 | O60674 | 1/20 | 0.40 |
| ▸ | JAK3 | P52333 | 1/20 | 0.40 |
| ▸ | SRC | P12931 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15036008 | 0.81 | TNK2 (0.42) | RIPK2TNK2ACVR1NOD2WEE1 | |
| SCHEMBL15785340 | 0.80 | PKN1 (0.45) | TNK2 | |
| SCHEMBL15041856 | 0.79 | RIPK2 (0.41) | RIPK2TNK2ACVR1NOD2WEE1 | |
| SCHEMBL13553811 | 0.77 | PKN1 (0.41) | TNK2WEE1SRC | |
| SCHEMBL15281605 | 0.77 | PKN1 (0.53) | RIPK2TNK2ACVR1NOD2WEE1 | |
| SCHEMBL15041593 | 0.77 | JAK2 (0.39) | RIPK2ACVR1NOD2PTK2WEE1 | |
| SCHEMBL15036047 | 0.77 | TNK2 (0.40) | RIPK2TNK2ACVR1NOD2WEE1 | |
| SCHEMBL14682078 | 0.76 | RIPK2 (0.42) | RIPK2TNK2ACVR1NOD2SRC | |
| SCHEMBL15281608 | 0.76 | PKN1 (0.47) | RIPK2TNK2ACVR1NOD2WEE1 | |
| SCHEMBL15030374 | 0.74 | WEE1 (0.70) | RIPK2PTK2WEE1AURKACDK4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8912203-B2 | 6-(sulfonylaryl)pyrido[2,3-D]pyrimidin-7(8H)-ones for the treatment of CNS disorders | AFRAXIS HOLDINGS, INC. (US) | 2014-12-16 | — | — | US | disclosed |
| US-8912203-B2 | 6-(sulfonylaryl)pyrido[2,3-D]pyrimidin-7(8H)-ones for the treatment of CNS disorders | AFRAXIS HOLDINGS, INC. (US) | 2014-12-16 | — | — | US | disclosed |
| US-20130158043-A1 | PAK INHIBITORS FOR THE TREATMENT OF CANCER | AFRAXIS, INC. (US) | 2013-06-20 | — | — | US | disclosed |
| US-20130158043-A1 | PAK INHIBITORS FOR THE TREATMENT OF CANCER | AFRAXIS, INC. (US) | 2013-06-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130158043-A1 | PAK INHIBITORS FOR THE TREATMENT OF CANCER | PAK5, PAK2, PAK6 | RIPK2 971/4885TNK2 7/4885ACVR1 4752/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.